The GI-MAP (Gastrointestinal Microbial Assay Plus) is a comprehensive stool test that uses quantitative polymerase chain reaction (qPCR) technology to detect over 50 gut microorganisms — including bacteria, parasites, viruses, and fungi — from a single stool sample. Unlike breath tests that measure gas output as a proxy for bacterial overgrowth, the GI-MAP directly identifies microbial DNA to tell you exactly what's living in your gut and how much of it is there. For SIBO patients, it fills critical diagnostic gaps: it can reveal underlying infections like H. pylori, detect parasites that mimic SIBO symptoms, assess digestive enzyme output, measure intestinal inflammation, and evaluate immune function. But it also has a significant limitation that every patient should understand — it tests stool, which primarily reflects the large intestine, not the small intestine where SIBO lives. Here's how to use it intelligently alongside breath testing for a complete picture.
What Is the GI-MAP Test?
The GI-MAP is a DNA-based stool test manufactured by Diagnostic Solutions Laboratory in Alpharetta, Georgia. It was developed specifically for clinical use and launched in 2014. Unlike culture-based stool tests — which grow bacteria on plates and can only detect organisms that survive outside the body — the GI-MAP uses quantitative PCR to amplify and measure microbial DNA directly. This means it can detect organisms that are difficult or impossible to culture, including anaerobic bacteria, parasites in cyst form, and viruses. The 'quantitative' part is key: rather than simply reporting whether an organism is present or absent, the GI-MAP provides a numeric count that tells clinicians how much of each organism is in the sample. This matters because many gut microbes are normal residents at low levels but become problematic when they overgrow. A standard culture-based test might report 'Candida detected' without distinguishing between a harmless trace and a clinically significant overgrowth. The GI-MAP gives you the number.
How qPCR Technology Works
Quantitative PCR (also called real-time PCR) is the same technology used in COVID-19 testing and forensic DNA analysis. The process works in three steps. First, DNA is extracted from your stool sample. Second, specific primers — short DNA sequences designed to match a target organism — bind to any matching microbial DNA in the sample. Third, the PCR machine amplifies (copies) that DNA through repeated heating and cooling cycles, doubling the amount with each cycle. A fluorescent marker glows brighter as more copies are made, and the machine measures how quickly the signal reaches a threshold. Fewer cycles to threshold means more of that organism was in the original sample. This gives a quantitative measurement expressed in scientific notation — for example, 3.2e4 means 32,000 copies of that organism's DNA were detected per gram of stool. The clinical reference ranges on the GI-MAP report indicate whether that quantity is normal, borderline, or elevated.
ℹ️qPCR is considered the gold standard for microbial detection because it can identify organisms that culture-based methods miss. Studies show qPCR detects 30-50% more pathogens than traditional stool cultures, particularly for parasites like Giardia and Cryptosporidium.
What the GI-MAP Tests: A Complete Breakdown
The GI-MAP panel covers six major categories. Understanding each one helps you interpret your results and see how they connect to SIBO.
| Category | Key Markers | Relevance to SIBO |
|---|---|---|
| Bacterial Pathogens | H. pylori (with virulence factors), C. difficile, E. coli (multiple strains), Campylobacter, Salmonella, Shigella | H. pylori reduces stomach acid, a major SIBO risk factor. C. difficile can flare after antibiotic treatment for SIBO. |
| Parasites | Giardia, Cryptosporidium, Entamoeba histolytica, Blastocystis hominis, Dientamoeba fragilis | Parasites cause symptoms identical to SIBO (bloating, diarrhea, fatigue) and can be the true underlying cause. |
| Viral Pathogens | Norovirus, Adenovirus, Rotavirus | Post-infectious IBS and SIBO often follow viral gastroenteritis. Identifies recent infections. |
| Fungi / Yeast | Candida albicans, Candida spp., Microsporidium, Geotricum | Candida overgrowth often coexists with SIBO and worsens after antibiotic treatment. |
| Commensal Bacteria | Lactobacillus, Bifidobacterium, Enterococcus, Bacteroides, Firmicutes, Akkermansia | Low beneficial bacteria suggests dysbiosis that predisposes to SIBO recurrence. |
| Digestive & Immune Markers | Pancreatic elastase, steatocrit, calprotectin, secretory IgA, anti-gliadin IgA, zonulin, beta-glucuronidase | Identifies enzyme deficiency, inflammation, leaky gut, and immune dysfunction driving SIBO. |
Key Digestive and Immune Markers Explained
The bottom section of the GI-MAP report — the digestive and immune markers — is often the most clinically useful part for SIBO patients. These markers reveal why SIBO developed and what's maintaining it.
Critical Markers for SIBO Patients
- Pancreatic elastase-1: Measures pancreatic enzyme output. Values below 200 µg/g indicate exocrine pancreatic insufficiency, which impairs digestion and creates undigested food for bacteria to ferment. Below 100 µg/g is severe insufficiency.
- Steatocrit: Measures fecal fat content. Elevated levels indicate fat malabsorption, common in SIBO due to bile acid deconjugation by overgrown bacteria.
- Calprotectin: A protein released by neutrophils during intestinal inflammation. Normal is below 120 µg/g. Elevated levels suggest inflammatory bowel disease, infection, or significant mucosal irritation — important for ruling out IBD before attributing symptoms to SIBO alone.
- Secretory IgA (sIgA): Your gut's first-line immune defense. Low sIgA (below 510 µg/mL) indicates immune exhaustion and increased susceptibility to infection and overgrowth. Elevated sIgA suggests active immune response to a current infection or irritant.
- Zonulin: A protein that regulates intestinal permeability (leaky gut). Elevated zonulin means tight junctions between intestinal cells are opening, allowing bacterial toxins and undigested food into the bloodstream — driving systemic inflammation.
- Beta-glucuronidase: An enzyme produced by certain gut bacteria that recirculates estrogen and toxins the liver has already packaged for elimination. Elevated levels indicate bacterial enzyme activity that can contribute to estrogen dominance and impaired detoxification.
- Anti-gliadin IgA: Measures immune reactivity to gluten. Elevated levels in the stool suggest mucosal immune response to gliadin, which can indicate celiac disease or non-celiac gluten sensitivity — both associated with increased SIBO risk.
GI-MAP vs. Breath Tests: What Each One Tells You
This is the most important distinction to understand: breath tests and the GI-MAP answer fundamentally different questions. A SIBO breath test asks, 'Is there bacterial overgrowth in the small intestine producing excess hydrogen, methane, or hydrogen sulfide?' The GI-MAP asks, 'What organisms are living in the gut, how many are there, and how is the digestive and immune system performing?' Neither test replaces the other. They are complementary.
| Feature | SIBO Breath Test | GI-MAP Stool Test |
|---|---|---|
| What it measures | Hydrogen, methane, and hydrogen sulfide gases | Microbial DNA, digestive enzymes, immune markers |
| Location tested | Small intestine (indirectly, via gas production) | Large intestine primarily (stool reflects colonic flora) |
| Detects specific organisms | No — only gas types | Yes — identifies species and quantities |
| Detects parasites | No | Yes |
| Detects H. pylori | No (separate breath test exists) | Yes, with virulence factors |
| Assesses digestion | No | Yes — elastase, steatocrit, bile acids |
| Assesses gut immune function | No | Yes — sIgA, calprotectin, zonulin |
| Directly diagnoses SIBO | Yes | No — stool does not reflect small intestinal content |
| Cost | $200-$350 | $350-$500 |
| Turnaround time | 5-10 days | 10-14 days |
What the GI-MAP Reveals That Breath Tests Miss
Breath tests are specifically designed to detect SIBO, and they do that job well. But they tell you nothing about why you have SIBO, what else might be going on, or what's likely to cause a relapse after treatment. The GI-MAP fills those gaps in several critical ways.
Diagnostic Gaps the GI-MAP Fills
- H. pylori infection: Present in roughly 50% of the global population, H. pylori suppresses stomach acid production. Low stomach acid allows bacteria to survive passage into the small intestine, directly causing SIBO. The GI-MAP detects H. pylori and its virulence factors (CagA, VacA), which determine how aggressively it needs to be treated.
- Parasitic infections: Giardia, Blastocystis, and Dientamoeba fragilis cause bloating, diarrhea, and fatigue that perfectly mimic SIBO. If you treat SIBO without identifying a concurrent parasite, your symptoms won't resolve. Standard stool cultures miss parasites roughly 50% of the time; qPCR is far more sensitive.
- Candida overgrowth: Fungal overgrowth commonly coexists with SIBO, especially after antibiotic treatment. Breath tests cannot detect yeast. The GI-MAP quantifies Candida species so you know if antifungal treatment is needed.
- Pancreatic insufficiency: Low elastase means your pancreas isn't producing enough digestive enzymes. Undigested food feeds bacterial overgrowth. This is a treatable root cause that breath tests cannot identify.
- Intestinal permeability: Elevated zonulin on the GI-MAP indicates leaky gut, which drives systemic symptoms like brain fog, joint pain, and skin issues in SIBO patients. This measurement helps guide gut-healing protocols beyond just killing bacteria.
- Immune deficiency: Low secretory IgA means your gut immune system isn't strong enough to prevent microbial overgrowth. Without addressing this, SIBO will keep coming back after treatment.
💡If you've treated SIBO multiple times and it keeps returning, the GI-MAP is especially valuable. Recurrent SIBO almost always has an underlying driver — H. pylori, parasites, low stomach acid, pancreatic insufficiency, or immune dysfunction — that the GI-MAP can identify.
Limitations of the GI-MAP for SIBO Diagnosis
Despite its strengths, the GI-MAP has a fundamental limitation for SIBO patients: it tests stool, and stool primarily reflects the microbial composition of the large intestine. SIBO, by definition, is an overgrowth in the small intestine. The small intestine and large intestine have vastly different bacterial populations — the large intestine contains roughly 10 trillion bacteria per milliliter of content, while the healthy small intestine contains fewer than 10,000. What shows up in stool has already passed through the entire GI tract, and the overwhelming colonic bacterial load dominates the signal. This means a GI-MAP cannot directly diagnose SIBO. You might have severe small intestinal overgrowth with a perfectly normal-looking GI-MAP commensal panel, because the colonic bacteria mask the small intestinal picture. Similarly, elevated pathogens on the GI-MAP might be living in the colon, not the small intestine. For this reason, the GI-MAP should never be used as a standalone SIBO test. It is a complementary tool that provides context, identifies co-infections, and reveals root causes — but a breath test remains the appropriate method for diagnosing SIBO itself.
How to Use the GI-MAP Alongside Breath Testing
The most effective diagnostic approach combines both tests strategically. Clinicians experienced with SIBO typically recommend the following workflow.
Recommended Testing Strategy
- Step 1: Start with a SIBO breath test (ideally a three-gas test measuring hydrogen, methane, and hydrogen sulfide) to confirm or rule out small intestinal overgrowth.
- Step 2: Run a GI-MAP simultaneously or shortly after to identify co-infections, root causes, and complicating factors.
- Step 3: Cross-reference results. For example, a positive methane SIBO breath test plus low elastase on the GI-MAP suggests both overgrowth and pancreatic insufficiency — the latter likely feeding the former.
- Step 4: Treat based on the combined picture. Address parasites and H. pylori first (if found), then treat SIBO, then rebuild the microbiome using the commensal panel as a guide.
- Step 5: Retest both after treatment to confirm resolution. The breath test confirms SIBO clearance; the GI-MAP confirms pathogen eradication and digestive improvement.
When to Order a GI-MAP Test
Not every SIBO patient needs a GI-MAP. If you have a straightforward case — your first episode, clear breath test results, obvious trigger like food poisoning — you may do fine with breath testing and standard treatment alone. But certain scenarios make the GI-MAP especially valuable.
Consider a GI-MAP If You Have
- Recurrent SIBO (two or more episodes despite appropriate treatment)
- Negative breath test but persistent SIBO-like symptoms
- History of international travel or suspected parasite exposure
- Symptoms that don't fully resolve after successful SIBO treatment
- Known or suspected H. pylori infection
- History of prolonged antibiotic or proton pump inhibitor use
- Autoimmune conditions, especially Hashimoto's thyroiditis or celiac disease
- Skin conditions like rosacea, eczema, or acne that accompany GI symptoms
Cost, Ordering, and Insurance Coverage
The GI-MAP typically costs between $350 and $500, depending on your practitioner's markup and whether additional add-on markers are included. It is ordered through a licensed healthcare provider — you cannot order it directly as a consumer from Diagnostic Solutions Laboratory. However, many functional medicine practitioners, naturopathic doctors, and integrative health providers routinely order it. Some direct-to-consumer lab services now offer the GI-MAP through their platforms with a telehealth consultation included in the price. Insurance coverage is limited. Most conventional insurance plans do not cover the GI-MAP because it is considered a specialty functional medicine test. Some patients have had success submitting the test to their insurer for partial reimbursement using the CPT codes provided on the lab requisition, but this is not guaranteed. HSA and FSA accounts can typically be used to pay for the GI-MAP, as it qualifies as a medical diagnostic expense.
How to Interpret Your GI-MAP Results
GI-MAP results are presented as a multi-page report with color-coded ranges: green (normal), yellow (borderline), and red (out of range). Each organism or marker shows a quantitative result in scientific notation alongside the reference range. While a trained practitioner should always review your results, understanding the basics helps you have an informed conversation. For pathogenic organisms, any detection above the reference range warrants attention. For commensal (beneficial) bacteria, you want to see values within or above the normal range — low levels indicate dysbiosis. For digestive markers, context matters: low elastase with high steatocrit paints a clear picture of pancreatic insufficiency and fat malabsorption, while elevated calprotectin alongside elevated pathogens suggests an active infection driving inflammation.
ℹ️The H. pylori section of the GI-MAP deserves special attention. It reports not just the presence of H. pylori but also virulence factors like CagA and VacA. CagA-positive strains are associated with higher risk of gastric ulcers and cancer, and tend to suppress stomach acid more aggressively — making SIBO more likely. If your GI-MAP shows CagA-positive H. pylori, eradication should be prioritized before or alongside SIBO treatment.
Can the GI-MAP diagnose SIBO?
No. The GI-MAP tests stool, which primarily reflects large intestinal bacteria. SIBO is an overgrowth in the small intestine. A breath test remains the appropriate diagnostic tool for SIBO. The GI-MAP is a complementary test that identifies co-infections, root causes, and complicating factors that breath tests cannot detect.
Should I do a GI-MAP or a breath test first?
If you suspect SIBO specifically, start with a breath test — it's cheaper, faster, and directly answers the SIBO question. If your breath test is negative but symptoms persist, or if you've had recurrent SIBO, add a GI-MAP to investigate deeper. Ideally, running both simultaneously gives the most complete picture.
How is the GI-MAP different from other stool tests like the GI Effects or CDSA?
The key difference is technology. The GI-MAP uses qPCR (DNA-based detection), while tests like the Genova GI Effects use a combination of culture, microscopy, and some PCR. qPCR is more sensitive and detects organisms that culture methods miss. The GI-MAP also provides fully quantitative results, while some other tests report semi-quantitative ranges like 'low/moderate/high.'
Do I need to stop probiotics before taking the GI-MAP?
Diagnostic Solutions Laboratory recommends stopping probiotics at least 2 weeks before collecting your sample to avoid artificially inflating Lactobacillus and Bifidobacterium levels on the commensal panel. You should also avoid antimicrobial herbs and antibiotics for at least 4 weeks prior, as these can suppress pathogen detection.
How often should I retest with the GI-MAP?
Most practitioners recommend retesting 6-8 weeks after completing a treatment protocol to confirm pathogen eradication and assess whether digestive markers have improved. For ongoing monitoring of chronic gut issues, every 6-12 months is a common cadence. There's no need to retest if your initial results were normal and symptoms have resolved.
⚠️This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.